6-K - Adagene Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Adagene Inc. announced a $70.0 million underwritten public offering of 18,666,000 ADSs at $3.75 per ADS, representing 23,332,500 ordinary shares, with gross proceeds expected before expenses and closing scheduled for April 6, 2026.

Key Takeaways

1Adagene is conducting a $70.0 million public offering of 18,666,000 ADSs at $3.75 each — direct equity capital raise to fund operations and development.

2Each ADS represents 1.25 ordinary shares, implying issuance of 23,332,500 newly issued ordinary shares — dilutive to existing shareholders.

3Leerink Partners and LifeSci Capital serve as joint book-running managers, with Lucid Capital Markets as co-manager — reflects established underwriter relationships in biotech.

4Offering is made under an effective Form F-3 shelf registration (File No. 333-287161), declared effective May 30, 2026 — enables efficient, timely capital access.

Current Report Details

Event Type

Securities Issuance

Disclosure

Voluntary

Variant

6-K

Items Reported

6-K

Current Report on Form 6-K

Securities Issuance

$3.75$70.0MUnderwriters, pursuant to which, subject to certain exceptions, they agreed not to offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant for the sale of, or otherwise dispose of or transfer any ADSs, ordinary shares or securities convertible into or exchangeable or exercisable for ADSs or ordinary shares for a period of 60 days following the date of prospectus supplement without the prior written consent of Leerink Partners

Exhibits (5)

1.1

EXHIBIT 1.1

5.1

EXHIBIT 5.1

6-K

FORM 6-K

8.1

EXHIBIT 8.1

99.1

EXHIBIT 99.1